Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| FG-3246 (ADC) | Cancer, Castration-resistant prostate cancer | Phase 2 | Dec 31, 2026 | Mgmt interest |
| FG-3180 (CD46 PET Tracer) | Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Dec 31, 2026 | Mgmt interest |
| FG-3246+ enzalutamide | Cancer, Castration-resistant prostate cancer | Phase 1/2 | TBA | — |
Upcoming milestones
Company profile
FibroGen Inc is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Cancer, Castration-resistant prostate cancer
UpdateCancer, Castration-resistant prostate cancer
Data readout